NEWTOWN, Pa.--(BUSINESS WIRE)--Quinnova Pharmaceuticals, Inc. announced today the launch of Salvax™ Duo, which contains one unit of Salvax™ Foam (containing 6% salicylic acid) and one unit of Hydro 40® Foam (containing 40% urea). Salvax™ Duo is available by prescription only and both Salvax™ Foam and Hydro 40® Foam are indicated for hyperkeratotic conditions such as dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma and dry, rough skin, as well as corns and calluses. Additionally, both products use Quinnova’s patented Proderm Technology™, a water-lipid based formulation that has anti-inflammatory, skin repair and protective properties.
